WellSpan Health-York Hospital

Summary

WellSpan Health-York Hospital is a medical facility located in York, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. WellSpan Health-York Hospital is involved with conducting 263 clinical trials across 335 conditions. There are 18 research doctors associated with this hospital, such as Amit B. Shah, Chanh T. Huynh, Dan Sotirescu, and William Nicholson.

Top PIs

Clinical Trials running at WellSpan Health-York Hospital

Lung Cancer

Ovarian Cancer

Breast Cancer

Stroke

Heart Failure

Prostate Cancer

Atrial Fibrillation

Pancreatic Cancer

Cancer

Breast cancer

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria